Rik Ossenkoppele

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7939807/publications.pdf

Version: 2024-02-01

274 papers	13,064 citations	30047 54 h-index	28275 105 g-index
329 all docs	329 docs citations	329 times ranked	9807 citing authors

#	Article	IF	Citations
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
2	PET Imaging of Tau Deposition in the Aging Human Brain. Neuron, 2016, 89, 971-982.	3.8	899
3	Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimerâ€™s disease. Brain, 2016, 139, 1551-1567.	3.7	833
4	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	3.8	501
5	The behavioural/dysexecutive variant of Alzheimerâ€™s disease: clinical, neuroimaging and pathological features. Brain, 2015, 138, 2732-2749.	3.7	397
6	Four distinct trajectories of tau deposition identified in Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 871-881.	15.2	354
7	Amyloid-Î²-independent regulators of tau pathology in Alzheimer disease. Nature Reviews Neuroscience, 2020, 21, 21-35.	4.9	338
8	Discriminative Accuracy of [¹⁸F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	3.8	298
9	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	4.9	254
10	Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain, 2017, 140, 3329-3345.	3.7	226
11	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	4.9	203
12	AÎ² deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimerâ€™s disease. Science Advances, 2020, 6, eaaz2387.	4.7	202
13	Atrophy patterns in early clinical stages across distinct phenotypes of <scp>A</scp>lzheimer's disease. Human Brain Mapping, 2015, 36, 4421-4437.	1.9	196
14	Associations between tau, AÎ², and cortical thickness with cognition in Alzheimer disease. Neurology, 2019, 92, e601-e612.	1.5	196
15	Functional brain architecture is associated with the rate of tau accumulation in Alzheimerâ€™s disease. Nature Communications, 2020, 11, 347.	5.8	185
16	Medial temporal lobe connectivity and its associations with cognition in early Alzheimerâ€™s disease. Brain, 2020, 143, 1233-1248.	3.7	164
17	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.	1.5	161
18	Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's and Dementia, 2013, 9, 414-421.	0.4	159

#	Article	IF	Citations
19	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimerâ€™s disease. Brain, 2017, 140, 2286-2294.	3.7	149
20	Longitudinal Amyloid Imaging Using ¹¹C-PiB: Methodologic Considerations. Journal of Nuclear Medicine, 2013, 54, 1570-1576.	2.8	148
21	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	4.5	148
22	Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 990-1000.	3.3	145
23	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurology, 2020, 77, 955.	4.5	136
24	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
25	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132
26	Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. Lancet Neurology, The, 2022, 21, 726-734.	4.9	130
27	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research and Therapy, 2020, 12, 118.	3.0	129
28	Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. NeuroImage: Clinical, 2018, 17, 452-464.	1.4	126
29	Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Annals of Neurology, 2015, 77, 338-342.	2.8	124
30	Untangling the association of amyloid-Î² and tau with synaptic and axonal loss in Alzheimerâ€™s disease. Brain, 2021, 144, 310-324.	3.7	123
31	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). Neurology, 2015, 84, 508-515.	1.5	122
32	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. Brain, 2012, 135, 2115-2125.	3.7	109
33	Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2014, 41, 801-807.	1.2	109
34	Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiology of Aging, 2012, 33, 2533-2550.	1.5	108
35	Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. Journal of Nuclear Medicine, 2013, 54, 894-902.	2.8	108
36	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology, 2018, 90, e149-e156.	1.5	103

#	Article	IF	Citations
37	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. JAMA Neurology, 2018, 75, 1062.	4.5	102
38	Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology, 2013, 80, 359-365.	1.5	99
39	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
40	Patient-centered connectivity-based prediction of tau pathology spread in Alzheimerâ€™s disease. Science Advances, 2020, 6, .	4.7	86
41	Cognitive reserve and clinical progression in Alzheimer disease. Neurology, 2019, 93, e334-e346.	1.5	85
42	Predicting diagnosis and cognition with ¹⁸Fâ€AVâ€1451 tau PET and structural MRI in Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 570-580.	0.4	84
43	Cerebral perfusion and glucose metabolism in Alzheimerâ€™s disease and frontotemporal dementia: two sides of the same coin?. European Radiology, 2015, 25, 3050-3059.	2.3	80
44	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	4.5	80
45	Frontotemporal dementia with the V337M MAPT mutation. Neurology, 2017, 88, 758-766.	1.5	76
46	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. Brain, 2020, 143, 2831-2843.	3.7	76
47	Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain. NeuroImage: Clinical, 2019, 23, 101848.	1.4	73
48	Distinct tau PET patterns in atrophyâ€defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.4	73
49	Prediction of AD dementia by biomarkers following the NIAâ€AA andÂIWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.4	71
50	Molecular imaging in dementia: Past, present, and future. Alzheimer's and Dementia, 2018, 14, 1522-1552.	0.4	68
51	Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnestic MCI: An European Alzheimer's Disease Consortium (EADC) Project. Journal of Alzheimer's Disease, 2015, 44, 815-826.	1.2	67
52	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurology, 2022, 79, 149.	4.5	66
53	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain, 2020, 143, 3805-3815.	3.7	65
54	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. Frontiers in Neuroscience, 2017, 11, 281.	1.4	62

#	Article	IF	Citations
55	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. Human Brain Mapping, 2017, 38, 4703-4715.	1.9	59
56	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. Radiology, 2016, 281, 865-875.	3.6	58
57	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
58	Tau PET correlates with different Alzheimerâ€™s diseaseâ€related features compared to CSF and plasma pâ€tau biomarkers. EMBO Molecular Medicine, 2021, 13, e14398.	3.3	58
59	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimerâ€™s disease. Brain, 2016, 139, 2528-2539.	3.7	58
60	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. ELife, 2019, 8, .	2.8	57
61	Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e102995.	1.1	56
62	Greater tau load and reduced cortical thickness in APOE Îµ4-negative Alzheimerâ€™s disease: a cohort study. Alzheimer's Research and Therapy, 2018, 10, 77.	3.0	56
63	Is intracranial volume a suitable proxy for brain reserve?. Alzheimer's Research and Therapy, 2018, 10, 91.	3.0	54
64	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology, 2014, 82, 1768-1775.	1.5	51
65	Applying the ATN scheme in a memory clinic population. Neurology, 2019, 93, e1635-e1646.	1.5	51
66	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2340-2347.	1.5	49
67	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology, 2022, 98, .	1.5	49
68	In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimer's Research and Therapy, 2021, 13, 35.	3.0	47
69	Clinical phenotype, atrophy, and small vessel disease in APOE Îµ2 carriers with Alzheimer disease. Neurology, 2018, 91, e1851-e1859.	1.5	46
70	Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods. Neurology, 2021, 97, 474-488.	1.5	46
71	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum. Neurology, 2021, 97, e1276-e1287.	1.5	44
72	Research Criteria for the Behavioral Variant of Alzheimer Disease. JAMA Neurology, 2022, 79, 48.	4.5	44

#	Article	IF	Citations
73	Quantification of Tau Load Using [18F]AV1451 PET. Molecular Imaging and Biology, 2017, 19, 963-971.	1.3	42
74	Sex differences in neuropsychiatric symptoms in Alzheimerâ€™s disease dementia: a meta-analysis. Alzheimer's Research and Therapy, 2022, 14, 48.	3.0	42
75	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimerâ€™s Disease. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 463-472.	1.1	41
76	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. Neurobiology of Aging, 2019, 79, 50-58.	1.5	41
77	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2295-2305.	3.3	41
78	Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimerâ€™s disease spectrum. Alzheimer's Research and Therapy, 2019, 11, 60.	3.0	40
79	Discordant amyloid-Î² PET and CSF biomarkers and its clinical consequences. Alzheimer's Research and Therapy, 2019, 11, 78.	3.0	40
80	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. Cerebral Cortex, 2019, 29, 2173-2182.	1.6	39
81	Amyloid and its association with default network integrity in Alzheimer's disease. Human Brain Mapping, 2014, 35, 779-791.	1.9	37
82	Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET. European Radiology, 2017, 27, 4237-4246.	2.3	37
83	Amyloid-Î² Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project. Frontiers in Aging Neuroscience, 2019, 11, 7.	1.7	37
84	Is Verbal Episodic Memory in Elderly with Amyloid Deposits Preserved Through Altered Neuronal Function?. Cerebral Cortex, 2014, 24, 2210-2218.	1.6	36
85	Mechanisms underlying resilience inÂageing. Nature Reviews Neuroscience, 2019, 20, 246-246.	4.9	34
86	Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimerâ€™s Disease Continuum. Cerebral Cortex, 2021, 31, 1-14.	1.6	34
87	Association of amyloid-Î² CSF/PET discordance and tau load 5 years later. Neurology, 2020, 95, e2648-e2657.	1.5	33
88	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimerâ€™s disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2110-2120.	3.3	33
89	Development and validation of language and visuospatial composite scores in ADNI. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12072.	1.8	29
90	Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2866-2878.	3.3	29

#	Article	IF	Citations
91	Differential associations of APOE-Îµ2 and APOE-Îµ4 alleles with PET-measured amyloid-Î² and tau deposition in older individuals without dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2212-2224.	3.3	29
92	Evidence-based Interpretation of Amyloid-Î² PET Results. Alzheimer Disease and Associated Disorders, 2018, 32, 28-34.	0.6	28
93	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3165-3175.	3.3	28
94	Dataâ€driven approaches for tauâ€PET imaging biomarkers in Alzheimer's disease. Human Brain Mapping, 2019, 40, 638-651.	1.9	27
95	Associations Between Caffeine Consumption, Cognitive Decline, and Dementia: A Systematic Review. Journal of Alzheimer's Disease, 2020, 78, 1519-1546.	1.2	27
96	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	3.3	27
97	Tau PET Imaging in Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 20S-26S.	2.8	26
98	Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1998-2008.	0.4	25
99	Comparison of Simplified Parametric Methods for Visual Interpretation of ¹¹C-Pittsburgh Compound-B PET Images. Journal of Nuclear Medicine, 2014, 55, 1305-1307.	2.8	24
100	The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster AÎ²â€associated tau accumulation and cognitive decline. Alzheimer's and Dementia, 2022, 18, 103-115.	0.4	24
101	Amyloid imaging in prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2011, 3, 26.	3.0	23
102	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. NeuroImage: Clinical, 2018, 19, 625-632.	1.4	23
103	Testâ€“retest repeatability of [¹⁸F]Flortaucipir PET in Alzheimerâ€™s disease and cognitively normal individuals. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 2464-2474.	2.4	23
104	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-Î²â€“negative cognitively normal individuals. Neurobiology of Aging, 2021, 97, 41-48.	1.5	23
105	The natural history of primary progressive aphasia: beyond aphasia. Journal of Neurology, 2022, 269, 1375-1385.	1.8	23
106	Intrinsic connectivity networks in posterior cortical atrophy: A role for the pulvinar?. NeuroImage: Clinical, 2019, 21, 101628.	1.4	22
107	Parametric methods for [¹⁸F]flortaucipir PET. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 365-373.	2.4	22
108	The strategic biomarker roadmap for the validation of Alzheimerâ€™s diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2070-2085.	3.3	22

#	Article	IF	Citations
109	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.4	22
110	PET and CSF amyloid-Î² status are differently predicted by patient features: information from discordant cases. Alzheimer's Research and Therapy, 2019, 11, 100.	3.0	21
111	A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus. EJNMMI Research, 2018, 8, 79.	1.1	19
112	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. Neurology, 2020, 95, e1672-e1685.	1.5	19
113	Amyloid imaging in clinical trials. Alzheimer's Research and Therapy, 2013, 5, 36.	3.0	18
114	The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease. Brain Connectivity, 2016, 6, 1-8.	0.8	18
115	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. Alzheimer's and Dementia, 2019, 15, 1458-1467.	0.4	18
116	Amyloidâ€Î² PET and CSF in an autopsyâ€confirmed cohort. Annals of Clinical and Translational Neurology, 2020, 7, 2150-2160.	1.7	17
117	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. Alzheimer's Research and Therapy, 2020, 12, 148.	3.0	17
118	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 872-880.	0.9	17
119	[11C]PIB amyloid quantification: effect of reference region selection. EJNMMI Research, 2020, 10, 123.	1.1	17
120	Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum. Neurology, 2022, 98, .	1.5	17
121	[¹⁸ F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers. Neurology, 2021, 97, e1017-e1030.	1.5	16
122	The Complexity of Subjective Cognitive Decline. JAMA Neurology, 2017, 74, 1400.	4.5	15
123	Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimerâ€™s disease: protocol of the BEAT-IT study. Alzheimer's Research and Therapy, 2019, 11, 48.	3.0	14
124	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimerâ€™s Disease1. Journal of Alzheimer's Disease, 2019, 68, 383-394.	1.2	14
125	Derivation and utility of an AÎ²-PET pathology accumulation index to estimate AÎ² load. Neurology, 2020, 95, e2834-e2844.	1.5	14
126	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimerâ€™s disease subgroups. NeuroImage: Clinical, 2021, 30, 102660.	1.4	13

#	Article	IF	Citations
127	The protective gene dose effect of the APOEÎµ2 allele on gray matter volume in cognitively unimpaired individuals. Alzheimer's and Dementia, 2022, 18, 1383-1395.	0.4	13
128	Genetically identical twins show comparable tau PET load and spatial distribution. Brain, 2022, 145, 3571-3581.	3.7	12
129	Prognostic value of Alzheimerâ€™s biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	1.8	11
130	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimerâ€™s disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2086-2096.	3.3	11
131	Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies. Molecular Imaging and Biology, 2021, 23, 604-613.	1.3	10
132	Tau-related grey matter network breakdown across the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2021, 13, 138.	3.0	10
133	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2259-2271.	3.3	10
134	Disease progression modelling from preclinical Alzheimerâ€™s disease (AD) to AD dementia. Scientific Reports, 2021, 11, 4168.	1.6	9
135	Differential trajectories of hypometabolism across cognitively-defined Alzheimerâ€™s disease subgroups. NeuroImage: Clinical, 2021, 31, 102725.	1.4	9
136	Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention. Journal of Nuclear Medicine, 2022, 63, 981-985.	2.8	9
137	Why Is Amyloid-Î² PET Requested After Performing CSF Biomarkers?. Journal of Alzheimer's Disease, 2020, 73, 559-569.	1.2	8
138	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1951-1963.	3.3	8
139	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1190-8.	3.3	7
140	Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Riskâ€”Reply. JAMA - Journal of the American Medical Association, 2015, 314, 1177.	3.8	6
141	Comorbid amyloidâ€Î² pathology affects clinical and imaging features in VCD. Alzheimer's and Dementia, 2020, 16, 354-364.	0.4	6
142	Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimerâ€™s Disease: A Case Report. Journal of Alzheimer's Disease, 2018, 66, 1363-1369.	1.2	5
143	Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. NeuroImage: Clinical, 2020, 25, 102113.	1.4	5
144	Association between APOE Îµ2 and AÎ² burden in patients with Alzheimer- and vascular-type cognitive impairment. Neurology, 2020, 95, e2354-e2365.	1.5	4

#	Article	IF	Citations
145	A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimerâ€™s Disease in Subjects with Mild Cognitive Impairment. Current Alzheimer Research, 2021, 17, 1186-1194.	0.7	4
146	Sex differences in neuropsychiatric symptoms in Alzheimerâ€™s disease dementia: A metaâ€analysis. Alzheimer's and Dementia, 2021, 17, .	0.4	4
147	The recognition and management of neuropsychiatric symptoms in early Alzheimer's disease: a qualitative study among Dutch memory clinic physicians. Psychogeriatrics, 0, , .	0.6	4
148	The biomarker roadmap for the validation for Alzheimerâ€™s biomarkers: Methodological update for biomarkers of tauopathy. Alzheimer's and Dementia, 2020, 16, e039063.	0.4	3
149	Alzheimerâ€™s disease biomarker roadmap 2020: Time for tau. Alzheimer's and Dementia, 2020, 16, e039549.	0.4	3
150	The BIN1 rs744373 Alzheimerâ€™s disease risk SNP is associated with faster AÎ²â€associated tau accumulation and cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	3
151	Biweekly fluctuations of neuropsychiatric symptoms according to the Neuropsychiatric Inventory: Erratic symptoms or scores?. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	3
152	P1â€318: TAUâ€PET Patterns Overlap and Exceed Hypometabolism in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P545.	0.4	2
153	[P1â€“311]: THE ROLE OF NEUROPSYCHIATRIC SYMPTOMS IN AD DIFFERENTIAL DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P372.	0.4	2
154	ICâ€Pâ€192: DISEASEâ€STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P158.	0.4	2
155	Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. Journal of Alzheimer's Disease, 2018, 65, 71-77.	1.2	2
156	Alzheimerâ€™s disease biomarker roadmap 2020: Fluid biomarkers. Alzheimer's and Dementia, 2020, 16, e039557.	0.4	2
157	Modeling patientâ€specific tau spreading patterns in Alzheimerâ€™s disease: Towards precision medicine. Alzheimer's and Dementia, 2020, 16, e040587.	0.4	2
158	Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e041048.	0.4	2
159	The accumulation rate of tau aggregates is higher in females and younger individuals. Alzheimer's and Dementia, 2020, 16, e043876.	0.4	2
160	The evolution of neuropsychiatric symptoms in atypical variants of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045236.	0.4	2
161	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. Molecular Imaging and Biology, 2021, 23, 550-559.	1.3	2
162	The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [18F]FDG-PET and pathological assessment. Neurocase, 2021, 27, 181-189.	0.2	2

#	Article	IF	Citations
163	Does Loss of Integrity of the Cingulum Bundle Link Amyloid-Î² Accumulation and Neurodegeneration in Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2022, 89, 39-49.	1.2	2
164	O4-01-05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P250-P250.		1
165	P2-196: RESTING STATE CEREBRAL PERFUSION AND METABOLISM IN SUBJECTIVE MEMORY COMPLAINTS: ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA-TWO SIDES OF THE SAME COIN?. , 2014, 10, P543-P543.		1
166	IC-P-010: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P12-P12.		1
167	IC-02-02: Distinct [18 F]AV1451 retention patterns in clinical variants of Alzheimer's disease. , 2015, 11, P5-P6.		1
168	O4-01-02: Associations of [18 F]AV1451 Tau PET with age, ApoE genotype, and cognition in Alzheimer's disease. , 2015, 11, P265-P266.		1
169	ICâ€Pâ€181: TAUâ€PET Patterns Overlap and Exceed Hypometabolism in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P132.	0.4	1
170	O1-07-05: Longitudinal Patterns of Cerebral Atrophy in Distinct Clinical Variants of Alzheimerâ€™s Disease. , 2016, 12, P191-P193.		1
171	[ICâ€Pâ€005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€Î² AND [¹⁸F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P13.	0.4	1
172	Genetic characterization of amyloid-Î² and tau network spread. Nature Medicine, 2018, 24, 1790-1792.	15.2	1
173	Alzheimerâ€™s disease biomarker roadmap 2020: Secondâ€generation tau PET tracers. Alzheimer's and Dementia, 2020, 16, e039556.	0.4	1
174	Differential effects of APOE2 and APOE4 alleles on PETâ€measured amyloidâ€Î² and tau deposition in older individuals without dementia. Alzheimer's and Dementia, 2020, 16, e040440.	0.4	1
175	Predictors of preclinical Alzheimerâ€™s disease in persons with subjective cognitive decline. Alzheimer's and Dementia, 2020, 16, e042658.	0.4	1
176	Heterogeneous distribution of pathology in behavioral variant Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e044830.	0.4	1
177	Quantification of Tau Load in Alzheimerâ€™s Disease Clinical Trials Using Positron Emission Tomography. Methods in Molecular Biology, 2018, 1750, 221-229.	0.4	1
178	Dementia Due to Neurodegenerative Disease: Molecular Imaging Findings. , 2014, , 185-211.		1
179	Disease Progression Course from Preclinical Stages of Alzheimer's Disease to Dementia: Distinct Progression by Sex and Apoe Îµ4. SSRN Electronic Journal, 0, , .	0.4	1
180	Untangling the roles of amyloid and tau in synaptic and axonal loss in the course of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e043169.	0.4	1

#	Article	IF	Citations
181	Updated prevalence estimates of amyloid positivity from cognitively normal to clinical Alzheimerâ€™s disease dementia: The Amyloid Biomarker Study. Alzheimer's and Dementia, 2021, 17, .	0.4	1
182	O4â€03â€01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, P618.	0.4	0
183	S1-02-03: Mild cognitive impairment associated with nonamyloid biomarker findings. , 2013, 9, P122-P122.		0
184	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
185	P2-194: PREVELANCE OF AMYLOID IN DEMENTED SUBJECTS. , 2014, 10, P542-P543.		0
186	IC-P-009: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P11-P12.		0
187	IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE. , 2014, 10, P48-P49.		0
188	O4-01-06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P250-P251.		0
189	O3-06-04: EFFECT OF APOE GENOTYPE ON THE PREVALENCE OF AMYLOID PATHOLOGY IN NON-DEMENTED SUBJECTS. , 2014, 10, P220-P220.		0
190	IC-02-03: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, P6-P6.		0
191	P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, P414-P414.		0
192	IC-P-157: Associations of [18 F]AV1451 Tau PET with age, ApoE genotype, and cognition in Alzheimer's disease. , 2015, 11, P105-P106.		0
193	F2-03-03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease. , 2015, 11, P168-P168.		0
194	IC-P-089: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P62-P62.		0
195	P4-100: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P814-P814.		0
196	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
197	F2-03-01: Tau and amyloid neuroimaging of ad phenotypes. , 2015, 11, P167-P167.		0
198	ICâ€Pâ€196: Quantification of TAU Load Using [¹⁸F]AVâ€1451 and PET. Alzheimer's and Dementia, 2016, 12, P141.	0.4	0

#	Article	IF	Citations
199	P1â€178: Impact of Coâ€Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders. Alzheimer's and Dementia, 2016, 12, P472.	0.4	0
200	ICâ€Pâ€097: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P74.	0.4	0
201	ICâ€Pâ€103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Nonâ€Demented Stages of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P78.	0.4	0
202	P4â€191: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P1095.	0.4	0
203	P4â€215: Quantification of Tau Load Using [¹⁸F]AVâ€1451 and Pet. Alzheimer's and Dementia, 2016, 12, P1109.	0.4	0
204	O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimerâ€™s Disease. , 2016, 12, P169-P170.		0
205	O1-11-03: Prevalence of Amyloid-b Pathology in Primary Progressive Aphasia Variants: A Multicenter Study. , 2016, 12, P202-P203.		0
206	O3â€08â€04: Tau Covariance Patterns in Alzheimer's Disease Patients Resemble Intrinsic Connectivity Networks in Young Adults. Alzheimer's and Dementia, 2016, 12, P305.	0.4	0
207	O3-09-02: Cognitive Consequences of Cerebral Amyloid Pathology in Persons without Dementia. , 2016, 12, P307-P308.		0
208	ICâ€Pâ€192: TAU Covariance Patterns in ad Patients Resemble Intrinsic Connectivity Networks in Young Adults. Alzheimer's and Dementia, 2016, 12, P138.	0.4	0
209	[P2â€“388]: INTRINSIC CONNECTIVITY NETWORKS IN POSTERIOR CORTICAL ATROPHY: A ROLE FOR THE PULVINAR?. Alzheimer's and Dementia, 2017, 13, P778.	0.4	0
210	[P2â€“407]: PREVALENCE OF AMYLOIDâ€PET POSITIVITY ACCORDING TO AGE AND APOE GENOTYPE IN PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P787.	0.4	0
211	[P3â€“407]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1120.	0.4	0
212	[P4â€“197]: EMERGING AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1340.	0.4	0
213	[P4â€“219]: [¹⁸F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P1352.	0.4	0
214	[P4â€“235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P1364.	0.4	0
215	[ICâ€Pâ€031]: INTRINSIC CONNECTIVITY NETWORKS IN POSTERIOR CORTICAL ATROPHY: A ROLE FOR THE PULVINAR?. Alzheimer's and Dementia, 2017, 13, P28.	0.4	0
216	[ICâ€Pâ€037]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P33.	0.4	0

#	Article	IF	Citations
217	[ICâ€Pâ€055]: EFFECT OF APOEâ€Îµ2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P45.	0.4	0
218	[ICâ€Pâ€106]: PREDICTING PROGRESSION IN PREâ€DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P81.	0.4	0
219	[ICâ€Pâ€203]: [¹⁸F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P148.	0.4	0
220	[ICâ€Pâ€206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P150.	0.4	0
221	[P1â€“575]: PREVALENCE OF THE APOLIPOPROTEIN E Îµ4 ALLELE IN AMYLOIDâ€Î² POSITIVE SUBJECTS ACROSS THE SPECTRUM OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P515.	0.4	0
222	[P2â€“207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€Î² AND [¹⁸F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P688.	0.4	0
223	[P2â€“335]: EFFECT OF APOE Îµ2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P748.	0.4	0
224	[O2â€“11â€“03]: PREDICTING PROGRESSION IN PREâ€DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P581.	0.4	0
225	[F4â€“01â€“01]: PET AND MRI STUDIES IN ATYPICAL VARIANTS OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1210.	0.4	0
226	[DTâ€01â€“02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2017, 13, P1474.	0.4	0
227	O3â€13â€01: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1054.	0.4	0
228	P3â€413: HETEROGENEOUS TAUâ€PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P1263.	0.4	0
229	ICâ€Pâ€222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P180.	0.4	0
230	O2â€04â€02: LONGITUDINAL COGNITIVE TRAJECTORIES OF PATIENTS WITH DISCORDANT CSF AND PET AMYLOID BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P621.	0.4	0
231	P2â€153: DIFFERENT CORTICAL NEURONAL VULNERABILITY IN DEMENTIA WITH AND WITHOUT PREDOMINANT BEHAVIOURAL SYMPTOMS. Alzheimer's and Dementia, 2018, 14, P726.	0.4	0
232	P2â€360: [¹⁸F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P827.	0.4	0
233	O2â€03â€03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, P615.	0.4	0
234	O2â€06â€01: [¹⁸F]FLORBETAPIR SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P630.	0.4	0

#	Article	IF	Citations
235	ICâ€Pâ€178: COMPARING HIPPOCAMPAL EFFECT SIZE BETWEEN ALZHEIMER'S DISEASE AND HEALTHY CONTROLS USING OLDER AND NEWER VERSIONS OF SPM AND FREESURFER. Alzheimer's and Dementia, 2018, 14, P150.	0.4	0
236	O2â€09â€06: FREQUENCIES OF CEREBROSPINAL FLUID A/T/N BIOMARKER PROFILES AND THEIR ASSOCIATION WITH MEMORY FUNCTION IN PERSONS WITHOUT DEMENTIA. Alzheimer's and Dementia, 2018, 14, P643.	0.4	0
237	ICâ€Pâ€224: HETEROGENEOUS TAUâ€PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P182.	0.4	0
238	ICâ€Pâ€110: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P94.	0.4	0
239	P2â€291: THE DIAGNOSTIC CHALLENGE OF NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE: A CASE REPORT. Alzheimer's and Dementia, 2018, 14, P792.	0.4	0
240	F5â€05â€04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1633.	0.4	0
241	P1â€467: DISEASEâ€STAGEâ€“SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P500.	0.4	0
242	P1â€430: EFFECTS OF APOE Îµ4 ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P473.	0.4	0
243	P3â€377: COMPARING HIPPOCAMPAL EFFECT SIZE BETWEEN ALZHEIMER'S DISEASE AND HEALTHY CONTROLS USING OLDER AND NEWER VERSIONS OF SPM AND FREESURFER. Alzheimer's and Dementia, 2018, 14, P1236.	0.4	0
244	P3â€585: COGNITIVE RESERVE MODULATES THE ASSOCIATION OF CEREBRAL AMYLOID PATHOLOGY WITH COGNITIVE PERFORMANCE IN PERSONS WITH ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1349.	0.4	0
245	F1â€04â€01: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2018, 14, P206.	0.4	0
246	O3â€04â€01: ASSOCIATIONS BETWEEN TAU, AÎ² AND CORTICAL THICKNESS WITH COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1018.	0.4	0
247	ICâ€Pâ€036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2018, 14, P39.	0.4	0
248	ICâ€Pâ€100: A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P87.	0.4	0
249	F2â€01â€01: NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P515.	0.4	0
250	ICâ€Pâ€079: SPATIAL DISTRIBUTION AND TOPOGRAPHICAL RELATIONSHIPS OF PATHOLOGY AND NEURODEGENERATION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P71.	0.4	0
251	ICâ€Pâ€076: FDGâ€PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELYâ€DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P68.	0.4	0
252	ICâ€Pâ€097: DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER'S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER'S DISEASE: THE VALUE OF NEUROIMAGING. Alzheimer's and Dementia, 2019, 15, P84.	0.4	0

#	Article	IF	Citations
253	Amyloidâ€Î² CSF/PET discordance vs tau load 5 years later: It takes two to tangle. Alzheimer's and Dementia, 2020, 16, e037246.	0.4	0
254	Alzheimerâ€™s disease biomarker roadmap 2020: [18 F]flortaucipir. Alzheimer's and Dementia, 2020, 16, e039550.	0.4	0
255	Accounting for systematic spatiotemporal variation improves connectomeâ€based models of tau spreading in human Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e040586.	0.4	0
256	Earlyâ€onset Alzheimerâ€™s disease is related to differential spatial patterns of tau pathology and cognitive impairment. Alzheimer's and Dementia, 2020, 16, e042041.	0.4	0
257	Diagnosis and management of neuropsychiatric symptoms in early Alzheimerâ€™s disease in the memory clinic setting. Alzheimer's and Dementia, 2020, 16, e045061.	0.4	0
258	Development and validation of composite scores for language and visuospatial functioning in ADNI. Alzheimer's and Dementia, 2020, 16, e045508.	0.4	0
259	The effects of mesial temporal tau in Abâ€negative cognitively normal older adults. Alzheimer's and Dementia, 2020, 16, e045607.	0.4	0
260	Quantitative accuracy remains after shortening of dynamic [18 F]flortaucipir PET protocol. Alzheimer's and Dementia, 2020, 16, e045710.	0.4	0
261	Assessment of cortical vulnerability of the anterior cingulate cortex in the behavioral variant of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045770.	0.4	0
262	Regional tau pathology is associated with loss of synapses and reduced synaptic activity: A combined [18 F]flortaucipir, [11 C]UCBâ€J and magnetoencephalography study. Alzheimer's and Dementia, 2020, 16, e045806.	0.4	0
263	Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. Alzheimer's and Dementia, 2020, 16, e045876.	0.4	0
264	Ability of tauâ€PET, phosphoâ€tau217, NfL and cortical thickness to predict shortâ€term cognitive decline in early symptomatic Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
265	Tau deposition is associated with grey matter network breakdown across different stages of the Alzheimerâ€™s disease continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	0
266	Longitudinal [¹⁸ F]flortaucipir PET: Comparison of quantitative and semiâ€quantitative parameters. Alzheimer's and Dementia, 2021, 17, .	0.4	0
267	Lower cognitive resilience against brain atrophy in cognitively unimpaired elderly is partly explained by Alzheimer's disease pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
268	Residual approaches to capture resilience and resistance in aging and Alzheimerâ€™s disease: A metaâ€analysis. Alzheimer's and Dementia, 2021, 17, .	0.4	0
269	Genetically identical twins are highly similar in levels and spatial distribution of tau pathology: A [¹⁸ F]flortaucipir PET study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
270	[¹⁸ F]RO948 tau PET in bvFTD due to C9orf72 and GRN mutations. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	Citations
271	A dataâ€driven latent atrophy factor model reveals differential associations between relative frontal atrophy patterns and specific neuropsychiatric symptoms in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
272	Tau PET as a prognostic marker in preclinical and prodromal Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
273	Associations between the APOEâ€Î¼2 and APOEâ€Î¼4 alleles with resistance and resilience against Alzheimerâ€™s disease pathology. Alzheimer's and Dementia, 2021, 17, e051346.	0.4	0
274	Do genetic factors contribute to sex-specific differences in resilience to amyloid pathology?. Brain, 0, , .	3.7	0